Clinical Trial Update: 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial is comparing 40.2 Gy versus 49.2 Gy radiotherapy in chemosensitive stage II nasopharyngeal carcinoma with low-risk target volumes; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Snippet

Sponsor: Ming-Yuan Chen | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: RECRUITING